Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509476 | 0.89 | HSP90AA1 (0.56) | HSP90AA1RAD52HSP90AB1DHFRADORA2A | |
| SCHEMBL697020 | 0.82 | DHFR (0.46) | HSP90AA1RAD52DHFRADORA2APTPN1 | |
| Hydrochloric Acid SCHEMBL509568 | 0.81 | DHFR (0.44) | HSP90AA1RAD52DHFRADORA2APTPN1 | |
| SCHEMBL510084 | 0.80 | GRM2 (0.46) | RAD52ADORA2AMEN1KMT2APOLB | |
| SCHEMBL10389070 | 0.80 | DHFR (0.46) | RAD52DHFRALDH1A1MEN1KMT2A | |
| SCHEMBL11374210 | 0.80 | HSP90AA1 (0.51) | HSP90AA1RAD52HSP90AB1DHFRADORA2A | |
| SCHEMBL509771 | 0.78 | KDM4E (0.52) | RAD52DHFRADORA2AALDH1A1GAA | |
| SCHEMBL509551 | 0.78 | RAD52 (0.52) | RAD52DHFRADORA2AALDH1A1MEN1 | |
| SCHEMBL11372347 | 0.77 | HSP90AA1 (0.51) | HSP90AA1RAD52HSP90AB1DHFRADORA2A | |
| SCHEMBL509700 | 0.77 | RAD52 (0.48) | HSP90AA1RAD52HSP90AB1DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532020-B | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives | REXAHN PHARMACEUTICALS INC | 2015-02-25 | — | — | CN | disclosed |
| US-8314123-B2 | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102532020-A | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS INC | 2012-07-04 | — | — | CN | disclosed |
| EP-2423196-A1 | 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| CN-101573337-B | 5, 6 or 7-substituted-3- (hetero) aryl-isoquinolinamine derivatives as antitumor agents | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-08 | — | — | CN | disclosed |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034829-B2 | e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. | REXAHN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| CN-101573337-A | 5, 6 or 7-substituted-3- (hetero) aryl-isoquinolinamine derivatives as antitumor agents | REXAHN PHARMACEUTICALS INC (US) | 2009-11-04 | — | — | CN | disclosed |
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | FANCD2, NRAS, CCND2 | HSP90AA1 3160/4885RAD52 542/4885HSP90AB1 2624/4885 |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | FANCD2, NRAS, CCND2 | HSP90AA1 3160/4885RAD52 542/4885HSP90AB1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.